Project Grant R21CA305031
Award Date 9/1/25
Completion Date 8/31/27
Dollars Obligated $400K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Chapel Hill, NC 27599, USA
Similar Awards
- The federal Project Grant award of $697,763 from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research by The University of Texas MD Anderson Cancer Center to decipher the critical determinants of how the Fusobacterium nucleatum (FN) bacteria colonizes the colorectal cancer (CRC) tumor microenvironment and contributes to disease progression. The project aims to gain mechanistic insights into how this oral bacteria homes to and persists within the CRC tumor, as...
- This federal Project Grant award in the amount of $159,540.00 was provided by the National Cancer Institute (CFDA 93.398 Cancer Research Manpower) to the University of North Carolina at Chapel Hill to conduct research aimed at characterizing and overcoming MHC-I-mediated immune evasion in triple-negative breast cancer. The key products and services to be delivered under this 2.5-year award include: 1) Functionally and molecularly characterizing MHC-I-low breast tumors to determine how MHC-I loss...
- This Project Grant award, provided by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), focuses on exploring the role of bacterial-derived small molecules in improving immunotherapy response rates and overall survival for non-small cell lung cancer patients. The $540,288 award to the University of Florida aims to test the central hypothesis that specific bacteria produce small molecules that can augment the efficacy and mitigate the toxicity of immune...
- This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $719,799 to Health Research, Inc. at Roswell Park in Buffalo, NY to conduct research on the impact of metabolic adaptations on the tumor microenvironment in metastatic triple-negative breast cancer (TNBC). The key objectives are to investigate the bifunctional mechanisms of the PFKFB4 enzyme in regulating metabolic and genetic plasticity in the TNBC tumor microenvironment, and to...
- This Project Grant award of $600,499.00 from the National Cancer Institute, under the Cancer Biology Research program (CFDA 93.396), supports research conducted by The Trustees of Columbia University in the City of New York (Health Sciences Division) to investigate the role of the Fusobacterium nucleatum (FN) bacterium and the Annexin A1 (ANXA1) protein as potential biomarkers in colorectal cancer oncogenesis. The key objectives of this 5-year project are to: (I) mechanistically investigate...
- The National Cancer Institute (NCI) awarded a $226,504 Project Grant (CFDA 93.396 - Cancer Biology Research) to the Rector & Visitors of the University of Virginia (UVA) to elucidate the role of B/T cell-enriched immune aggregates in immune surveillance against triple-negative breast cancer (TNBC). The project aims to study how these novel immune aggregates form and function to control pre-malignant progression of TNBC, which could inform future strategies to enhance immune surveillance...
- This federal Project Grant award of $606,839.00, provided by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research), supports research to identify gut microbiota that actively deplete intestinal amino acids and evaluate how they affect the tumor microenvironment and cancer progression. The primary awardee is Weill Medical College of Cornell University, a leading academic medical institution with expertise in biomedical research and translational science. The project aims to...
- This federal Project Grant award for $442,750.00, provided by the National Institute of Dental and Craniofacial Research (NIDCR) under the Oral Diseases and Disorders Research program (CFDA 93.121), supports research to systematically identify the drivers controlling interactions between the bacterium Fusobacterium nucleatum (FN) and oral squamous cell carcinoma. The research aims to: 1) identify tumor cell determinants of FN invasion and altered tumor cell viability, and 2) identify microbial...
- This $421,685 federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research conducted by the University of California, San Francisco (UCSF) to investigate the "reactive" immune system in tumors and the tumor microenvironment. The study aims to discover discrete immune cell niches within the tumor that can enhance the effectiveness of cancer immunotherapies. Using innovative spatial transcriptomics, genetic tools, and cellular...
- This $137,322 Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) supports research by Trustees of Boston University to develop disulfated polyamidosaccharide nanoparticles as a P-selectin targeting chemotherapeutic delivery system. The goal is to create a more targeted and effective treatment for breast and lung cancers, which disproportionately affect women, including many non-smokers. The research will leverage the upregulation of P-selectin on...